GlassScriptPhysician profile
Seth A Vaccaro
NPI 1477560951
$4,847.37
in general payments reported to CMS, 2019-2025
29 companies · $754 in 2025
The $754 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $34.35 · 2021: $122 · 2022: $614 · 2023: $1,526 · 2024: $1,411 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,583 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,583.16 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.42 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Genzyme Corporation | $809.53 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $448.74 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $281.60 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $236.19 | 2019-2025 | |
| Dermavant Sciences, INC. | $223.02 | 2023-2024 | Vtama |
| Amgen INC. | $211.89 | 2020-2025 | Otezla, Otezla |
| Almirall LLC | $198.78 | 2022-2023 | Klisyri |
| Pfizer INC. | $191.10 | 2019-2024 | |
| Ucb, INC. | $190.45 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $189.04 | 2022-2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $130.61 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $122.70 | 2019-2025 | Tremfya |
| Allergan, INC. | $119.40 | 2019-2022 | |
| Leo Pharma INC. | $97.44 | 2019-2025 | Adbry |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $91.54 | 2019-2024 | Oracea, Epsolay, Aklief |
| Sun Pharmaceutical Industries INC. | $90.24 | 2022-2024 | Winlevi, Absorica Ld |
| Merz North America, INC. | $89.87 | 2024-2025 | |
| Incyte Corporation | $68.76 | 2022-2025 | Opzelura |
| Journey Medical Corporation | $39.66 | 2022-2025 | |
| Epi Health, LLC | $32.97 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.78 | 2019 | |
| Boston Scientific Corporation | $26.40 | 2021 | |
| Organogenesis INC. | $21.98 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.96 | 2024 | Cyltezo |
| Kyowa Kirin, INC. | $19.73 | 2023 | Poteligeo |
| Biofrontera INC. | $19.57 | 2019 | |
| Sientra, INC. | $19.00 | 2019 | |
| Mayne Pharma Commercial LLC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Vaccaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.